Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Comparison of the effects of zardaverine and theophylline on pulmonary function in rats.

Vergleich der Effekte von Zardaverine und Theophylline auf die Lungenfunktion an Ratten
 
: Hoymann, H.G.; Heinrich, U.; Beume, R.; Kilian, U.

Journal of Aerosol Medicine 4 (1991), Supplement No.1, pp.70 ff
ISSN: 0894-2684
ISAM <1991, Davos>
English
Conference Paper
Fraunhofer ITA ( ITEM) ()
Asthma; bronchial provocation test; bronchialer Provokationstest; Lungenfunktionstest; posphodiesterase inhibitor; rat; Ratte; respiratory function test; theophylline; zardaverine

Abstract
Zardaverine is a new selective PDE III/IV inhibitor with potent bronchospasmolytic activity in guinea pigs. We recently compared the bronchodilating and bronchoprotective potency of zardaverine and the nonselective PDE inhibitor theophylline by measuring typical spontaneous and forced respiratory function parameters in anaesthetized rats using whole-body plethysmography. 60 female Wistar rats (240 g) were used in the experiment. Zardaverine (3, 10, 30 mymol/kg) and theophylline (30, 100, 300 mymol/kg), respectively, were given orally in 4% Methocel/0.9% saline solution after more than 15 h starving. 20 min after treatment the measurements were started. One week earlier, to obtain control values, measurements were performed 20 min after feeding the vehicle. When spontaneously breathing, the 30 mymol/kg zardaverine (300 mymol/kg theophylline) treated animals showed a 23% (14%, ns) decreased lung resistance and a 43% (25%) elevated dynamic compliance. There was no indication of a changed lung elasticity based on quasistatic compliance and therefore the increased dynamic compliance as well as the decreased resistance can only be caused by bronchodilation. In the acetylcholine challenge test treatment with only 10 mymol/kg zardaverine (but 300 mymol/kg theophylline) revealed a 37% (28%) lower resistance and 85% (44%) higher compliance. This indicates a better bronchoprotective effect of zardaverine which was also supported by Peak Flow, FEF sub 50 and FEF sub 25 measurement after challenge.

: http://publica.fraunhofer.de/documents/PX-8225.html